Merck's stock gained 239% over the past decade, with a remarkable 95% surge in the last year fueled by strong sales of its cancer immunotherapy Keytruda and acquisitions like Verona Pharma and Cidara. Despite some setbacks in other products, Merck's revenue rose significantly, and its forward price-to-earnings ratio suggests solid earnings potential. The company faces a critical period as Keytruda patents expire, but new drugs and pipeline developments could sustain growth. Investors are advised to hold through the transition, as the recent surge rewards long-term patience rather than short-term trading.
Merck's market capitalization stands at $366.84 billion as of September 29, 2026, with a dividend yield of 2.29%, indicating steady returns for shareholders. On Pluang, Merck's stock price is $147.19, showing a slight 1.02% decline on the day, while trading volume reached 7,522,303 shares. The typical hold time of 98 days on Pluang suggests investors are moderately patient with this health sector stock amid its ongoing transition period.
